Zelluna Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
ZLNA
- Investments
-
1
- Share Price
-
$1.68
- (As of Thursday Closing)
Zelluna General Information
Description
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
Contact Information
Website
www.zelluna.comCorporate Office
- Ullernchausséen 64
- 0379 Oslo
- Norway
Corporate Office
- Ullernchausséen 64
- 0379 Oslo
- Norway
Zelluna Timeline
Zelluna Stock Performance
As of 12-Nov-2026, Zelluna’s stock price is $1.68. Its current market cap is $50.3M with 29.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.68 | $1.73 | $0.80 - $3.82 | $50.3M | 29.9M | 64.2K | -$0.41 |
Zelluna Financials Summary
As of 30-Sep-2026, Zelluna has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 53,012 | 31,493 | (4,250) | 385,176 |
| Revenue | 0 | 0 | 5 | 0 |
| EBITDA | (10,285) | (13,396) | (9,671) | (18,938) |
| Net Income | (10,686) | (13,523) | (9,756) | (17,866) |
| Total Assets | 9,996 | 30,635 | 10,013 | 34,319 |
| Total Debt | 84 | 0 | 185 | 365 |
Zelluna Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zelluna Comparisons
Industry
Financing
Details
Zelluna Competitors (70)
One of Zelluna’s 70 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| DEM BioPharma | Venture Capital-Backed | Cambridge, MA |
Zelluna Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zelluna Patents
Zelluna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024311300-A1 | Methods of enhancing or modifying nk cells | Pending | 20-Jun-2023 | ||
| EP-4731252-A1 | Methods of enhancing or modifying nk cells | Pending | 20-Jun-2023 | ||
| US-20260308525-A1 | Methods of enhancing or modifying nk cells | Pending | 20-Jun-2023 | ||
| WO-2024261045-A1 | Methods of enhancing or modifying nk cells | Inactive | 20-Jun-2023 | ||
| GB-202303626-D0 | Compositions and methods for immunotherapy | Inactive | 13-Mar-2023 |
Zelluna Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zelluna Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zelluna Acquisitions (1)
Zelluna’s most recent deal was a Merger/Acquisition with Ultimovacs for . The deal was made on 03-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ultimovacs | 03-Mar-2025 | Merger/Acquisition | Biotechnology |
Zelluna ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Zelluna FAQs
-
When was Zelluna founded?
Zelluna was founded in 2016.
-
Where is Zelluna headquartered?
Zelluna is headquartered in Oslo, Norway.
-
What is the size of Zelluna?
Zelluna has 15 total employees.
-
What industry is Zelluna in?
Zelluna’s primary industry is Drug Discovery.
-
Is Zelluna a private or public company?
Zelluna is a Public company.
-
What is Zelluna’s stock symbol?
The ticker symbol for Zelluna is ZLNA.
-
What is the current stock price of Zelluna?
As of 12-Nov-2026 the stock price of Zelluna is $1.68.
-
What is the current market cap of Zelluna?
The current market capitalization of Zelluna is $50.3M.
-
Who are Zelluna’s competitors?
Aura Biosciences, Celldex, Carisma Therapeutics, Kite Pharma, and DEM BioPharma are some of the 70 competitors of Zelluna.
-
What is Zelluna’s annual earnings per share (EPS)?
Zelluna’s EPS for 12 months was -$0.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
